Carbonic anhydrase V : Questions médicales fréquentes
Nom anglais: Carbonic Anhydrase V
Descriptor UI:D024404
Tree Number:D08.811.520.241.300.150.500
Termes MeSH sélectionnés :
Attention Deficit Disorder with Hyperactivity
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carbonic anhydrase V : Questions médicales les plus fréquentes",
"headline": "Carbonic anhydrase V : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carbonic anhydrase V : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-01",
"dateModified": "2025-02-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carbonic anhydrase V"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Carbonic anhydrases",
"url": "https://questionsmedicales.fr/mesh/D002256",
"about": {
"@type": "MedicalCondition",
"name": "Carbonic anhydrases",
"code": {
"@type": "MedicalCode",
"code": "D002256",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.520.241.300.150"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carbonic anhydrase V",
"alternateName": "Carbonic Anhydrase V",
"code": {
"@type": "MedicalCode",
"code": "D024404",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Claudiu T Supuran",
"url": "https://questionsmedicales.fr/author/Claudiu%20T%20Supuran",
"affiliation": {
"@type": "Organization",
"name": "Department of Neuroscience, Psycology, Drug Research and Child Health (NEUROFARBA), Section of Pharmaceutical Sciences, University of Florence, 50019 Florence, Italy."
}
},
{
"@type": "Person",
"name": "Alessio Nocentini",
"url": "https://questionsmedicales.fr/author/Alessio%20Nocentini",
"affiliation": {
"@type": "Organization",
"name": "Department of Neuroscience, Psycology, Drug Research and Child Health (NEUROFARBA), Section of Pharmaceutical Sciences, University of Florence, 50019 Florence, Italy."
}
},
{
"@type": "Person",
"name": "Clemente Capasso",
"url": "https://questionsmedicales.fr/author/Clemente%20Capasso",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Bioscienze e Biorisorse - Consiglio Nazionale delle Ricerche CNR, Via P: Castellino 111, 80131, Naples, Italy."
}
},
{
"@type": "Person",
"name": "Andrea Angeli",
"url": "https://questionsmedicales.fr/author/Andrea%20Angeli",
"affiliation": {
"@type": "Organization",
"name": "Neurofarba Department, University of Florence, Sesto Fiorentino, Florence, Italy. Electronic address: andrea.angeli@unifi.it."
}
},
{
"@type": "Person",
"name": "Fabrizio Carta",
"url": "https://questionsmedicales.fr/author/Fabrizio%20Carta",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurofarba, University of Florence, 50019 Sesto Fiorentino, Italy. fabrizio.carta@unifi.it."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Attention Deficit Hyperactivity Disorder (ADHD) and the gut microbiome: An ecological perspective.",
"datePublished": "2023-08-18",
"url": "https://questionsmedicales.fr/article/37594987",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0273890"
}
},
{
"@type": "ScholarlyArticle",
"name": "Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37430151",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40263-023-01023-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigating young-adult social outcomes of attention deficit hyperactivity disorder.",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36922989",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4088/jcp.22m14379"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cannabis use in Attention - Deficit/Hyperactivity Disorder (ADHD): A scoping review.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36508935",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpsychires.2022.11.029"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using",
"datePublished": "2022-11-07",
"url": "https://questionsmedicales.fr/article/36317558",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/00498254.2022.2141151"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lyases",
"item": "https://questionsmedicales.fr/mesh/D008190"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carbon-oxygen lyases",
"item": "https://questionsmedicales.fr/mesh/D019757"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hydro-lyases",
"item": "https://questionsmedicales.fr/mesh/D006836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Carbonic anhydrases",
"item": "https://questionsmedicales.fr/mesh/D002256"
},
{
"@type": "ListItem",
"position": 8,
"name": "Carbonic anhydrase V",
"item": "https://questionsmedicales.fr/mesh/D024404"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carbonic anhydrase V - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carbonic anhydrase V",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carbonic anhydrase V",
"description": "Comment diagnostiquer une anomalie de l'anhydrase carbonique V ?\nQuels symptômes peuvent indiquer un problème avec l'anhydrase carbonique V ?\nY a-t-il des tests spécifiques pour l'anhydrase carbonique V ?\nQuel rôle joue l'imagerie dans le diagnostic ?\nLes antécédents familiaux sont-ils importants pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D024404?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carbonic anhydrase V",
"description": "Quels sont les symptômes d'une déficience en anhydrase carbonique V ?\nPeut-on avoir des symptômes neurologiques ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques chez les enfants ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D024404?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carbonic anhydrase V",
"description": "Peut-on prévenir les troubles liés à l'anhydrase carbonique V ?\nY a-t-il des mesures préventives spécifiques ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nLes femmes enceintes doivent-elles être surveillées ?\nL'éducation des patients est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D024404?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carbonic anhydrase V",
"description": "Quels traitements sont disponibles pour les troubles liés à l'anhydrase carbonique V ?\nLa thérapie génique est-elle une option ?\nLes changements de mode de vie peuvent-ils aider ?\nY a-t-il des médicaments spécifiques à éviter ?\nLes traitements sont-ils différents pour les enfants ?",
"url": "https://questionsmedicales.fr/mesh/D024404?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carbonic anhydrase V",
"description": "Quelles sont les complications possibles d'une déficience en anhydrase carbonique V ?\nLes complications peuvent-elles affecter le développement ?\nY a-t-il des risques de maladies associées ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D024404?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carbonic anhydrase V",
"description": "Quels sont les facteurs de risque pour les troubles de l'anhydrase carbonique V ?\nL'environnement joue-t-il un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'âge est-il un facteur de risque ?\nLes habitudes de vie influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D024404?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de l'anhydrase carbonique V ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses génétiques peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec l'anhydrase carbonique V ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles respiratoires ou des déséquilibres acido-basiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour l'anhydrase carbonique V ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques peuvent mesurer l'activité de l'enzyme dans le sang."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les complications associées, comme les lésions tissulaires."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils importants pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux peuvent indiquer une prédisposition génétique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en anhydrase carbonique V ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, troubles respiratoires et déséquilibres électrolytiques."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des maux de tête peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la condition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les enfants ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent présenter des retards de développement et des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent s'aggraver et entraîner des complications."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à l'anhydrase carbonique V ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter les problèmes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en nutriments et une bonne hydratation peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les personnes à risque et permettre une surveillance."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance pendant la grossesse est recommandée pour éviter des complications."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les symptômes et les soins peut aider à une détection précoce."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés à l'anhydrase carbonique V ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des suppléments électrolytiques et des médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour cette condition."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée et une hydratation adéquate peuvent améliorer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques à éviter ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains diurétiques peuvent aggraver les symptômes et doivent être évités."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents pour les enfants ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction de l'âge et des besoins spécifiques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles d'une déficience en anhydrase carbonique V ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles respiratoires graves et des déséquilibres électrolytiques."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications peuvent entraîner des retards de développement chez les enfants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies rénales et pulmonaires peuvent être associées à cette condition."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier avec des tests sanguins et des examens cliniques est essentiel."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles de l'anhydrase carbonique V ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux et certaines conditions génétiques."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme l'exposition à des toxines peuvent influencer la condition."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de troubles liés à l'enzyme."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles peuvent se manifester plus fréquemment chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie comme le tabagisme peuvent augmenter le risque de complications."
}
}
]
}
]
}
Attention Deficit Hyperactivity Disorder (ADHD) is an increasingly prevalent neuropsychiatric disorder characterized by hyperactivity, inattention, and impulsivity. Symptoms emerge from underlying def...
In our outpatient pediatric and adult psychiatry centers, we reserve psychostimulants for predominantly inattentive attention deficit hyperactivity disorder (ADHD) due to the potential for appetite an...
50 patients (35 children) received mean doses of atomoxetine 60 mg (25-100 mg once daily) followed by VER 300 mg (100-600 mg once daily) after a 5-day atomoxetine washout. Both atomoxetine and VER wer...
From the baseline total ADHD-RS-5 mean score (40.3 ± 10.3), improvements were greater on VER (13.9 ± 10.2) than atomoxetine (33.1 ± 12.1; t = - 10.12, p < 0.00001) in inattention (t = - 8.57, p < 0.00...
Pediatric and adult ADHD patients who have experienced less than optimal response to atomoxetine demonstrate rapid improvement in inattention and in hyperactivity/impulsivity with greater tolerability...
Attention Deficit Hyperactivity Disorder (ADHD) is associated with a range of adverse outcomes in adult life. However it is unclear whether the risk pathways to adverse adult outcomes are established ...
We examined associations between broadly defined child-limited (remitted) and persistent ADHD (assessed using the ADHD subscale of the Strengths and Difficulties Questionnaire) with social outcomes (l...
Up to 20% of young-people with less favourable social outcomes at age 25 had persistent ADHD. Persistent ADHD was associated with an increased likelihood of being not in education, employment or train...
Our findings highlight the importance of continued monitoring and management of ADHD symptoms and related social as well as clinical outcomes across development into adulthood. Future research is need...
Treatments for Adult ADHD include stimulants, two non-stimulant medications, as well as cognitive-behavioral therapy (CBT). These pharmacological agents are often associated with side effects, contrib...
We systematically searched MEDLINE, EMBASE, EMCARE, PsycINFO, Web of Science, Cochrane Library, and Clinicaltrials.gov. The searches included all publications in English up to June 27, 2022. We includ...
Our scoping review included a total of 39 studies. Only one study employed a randomized and placebo-controlled design to directly measure the effect of cannabis on ADHD, and no significant effect was ...
Given the current evidence, cannabis is not recommended for people with ADHD. Limitations of the literature include the absence of objective measurements for cannabis exposure and ADHD symptoms, heter...
Abnormal cerebellar development has been implicated in attention-deficit/hyperactivity disorder (ADHD), although cerebro-cerebellar functional connectivity (FC) has yet to be examined in ADHD. Our obj...
We analyzed a dataset of 106 individuals with ADHD (68 children, 38 adolescents) and 62 healthy comparison individuals (34 children, 28 adolescents) from the publicly available ADHD-200 dataset. We id...
Compared to comparisons, ADHD showed higher cerebro-cerebellar FC in the superior temporal gyrus within the somatomotor network. Interactions of diagnosis and age were identified in the supplementary ...
Increased cerebro-cerebellar FC in the superior temporal gyrus within the somatomotor network could underlie impairments in cognitive control and somatic motor function in ADHD. In addition, increasin...
Children with attention-deficit hyperactivity disorder (ADHD) experience substantial difficulty maintaining meaningful friendships, which has implications for social functioning and mental health. No ...
To systematically review and methodologically appraise the quality of existing studies reporting on friendships of children with ADHD. To compare their friendships to typically-developing children, an...
Six databases were searched. The methodological quality of studies was assessed using the QualSyst appraisal tool and the Appraisal tool for Cross-Sectional Studies. Aspects of friendships measured we...
Twenty-three cross-sectional studies and one longitudinal follow-up study were included. Studies included 1509 participants with ADHD, with 1197 typically-developing participants used as a companion i...
Limited longitudinal studies, small sample sizes and variability in measurement restrict the interpretations of friendship over time and the causal impact of friendship on social and emotional outcome...
To describe the process of collaborative, contextualised development and implementation of a model of care for adults with symptoms suggestive of attention deficit and hyperactivity disorder in an Abo...
The current article describes an attempt to reduce unmet mental health needs through a systemic approach within a well-established Indigenous community-controlled organisation....
Observational studies have found an association between attention-deficit/hyperactivity disorder (ADHD) and ischemic stroke....
The purpose of this study was to investigate whether genetic liability to ADHD has a causal effect on ischemic stroke and its subtypes....
In this two-sample Mendelian randomization (MR) study, genetic variants (nine single-nucleotide polymorphisms;...
Genetically determined ADHD (per 1 SD) was significantly associated with a higher risk of any ischemic stroke (AIS) (odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.05-1.25,...
Genetic liability to ADHD was significantly associated with an increased risk of AIS, especially LAS. The association between ADHD and LAS was independent of age of smoking initiation but mediated by ...